MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
Kyverna Therapeutics (KYTX) stock jumps as the company posts new mid-stage trial data for its lead asset, miv-cel, in generalized myasthenia gravis. Read more here.
Pooled efficacy favored ravulizumab, improving QMG (MD –2.91) and MG-ADL (MD –2.64) after ~25 weeks, despite substantial between-study heterogeneity. Clinically meaningful MG-ADL response (≥2-point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results